LASIX Drug Patent Profile

Which patents cover Lasix, and when can generic versions of Lasix launch?

Lasix is a drug marketed by Sanofi Aventis Us, Validus Pharms, and Sq Innovation. and is included in four NDAs.

The generic ingredient in LASIX is furosemide. There are twenty-two drug master file entries for this compound. Sixty suppliers are listed for this compound. Additional details are available on the furosemide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lasix

A generic version of LASIX was approved as furosemide by ESJAY PHARMA on July 27^th, 1982.

Summary for LASIX

US Patents:	0
Applicants:	3
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	108
Patent Applications:	3,014
Drug Prices:	Drug price information for LASIX
What excipients (inactive ingredients) are in LASIX?	LASIX excipients list
DailyMed Link:	LASIX at DailyMed

See drug prices for LASIX

See drug sales revenues for LASIX

Pharmacology for LASIX

Drug Class	Loop Diuretic
Physiological Effect	Increased Diuresis at Loop of Henle

US Patents and Regulatory Information for LASIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LASIX	furosemide	INJECTABLE;INJECTION	016363-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Validus Pharms	LASIX	furosemide	TABLET;ORAL	016273-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Sanofi Aventis Us	LASIX	furosemide	SOLUTION;ORAL	017688-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for LASIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	LASIX	furosemide	INJECTABLE;INJECTION	016363-001	Approved Prior to Jan 1, 1982
Sanofi Aventis Us	LASIX	furosemide	SOLUTION;ORAL	017688-001	Approved Prior to Jan 1, 1982
Validus Pharms	LASIX	furosemide	TABLET;ORAL	016273-003	Approved Prior to Jan 1, 1982

International Patents for LASIX

See the table below for patents covering LASIX around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	455274
Mexico	3585
Germany	2343218

Market Dynamics and Financial Trajectory for LASIX (Furosemide)

Last updated: January 12, 2026

Executive Summary

LASIX (furosemide), a loop diuretic primarily used for edema associated with congestive heart failure, liver cirrhosis, and renal disease, remains a critical therapeutic agent despite patent expirations and increasing generic competition. The global LASIX market is defined by evolving regulatory policies, patent expirations, manufacturing dynamics, and competitive pressures. This analysis explores key market drivers, revenue streams, competitive landscape, and future projections for LASIX over the next decade. It also discusses factors influencing pricing, volumes, and emerging market opportunities, providing stakeholders with a comprehensive understanding of LASIX’s financial trajectory.

---

What Are the Current Market Drivers for LASIX?

1. Clinical Demand and Therapeutic Significance

• Prevalence of Cardiovascular and Renal Diseases: According to the WHO, cardiovascular diseases (CVD) account for 17.9 million deaths annually, with a significant subset requiring diuretics like LASIX. The global burden of renal impairment and liver cirrhosis further sustains demand.
• Established Therapeutic Efficacy: LASIX’s proven efficacy in edema and hypertension management underpins its continuous clinical demand.

2. Patent Expiry and Generic Competition

• The original patent on LASIX expired decades ago (patent generally expired in 1985), leading to extensive generic manufacturing, which drives down prices and increases accessibility.
• Generic Market Penetration: Generic versions constitute over 90% of volumes in major markets, such as the US and EU, drastically reducing revenues per unit but compensating with high volumes.

3. Regulatory and Pricing Dynamics

• Regulatory agencies like the FDA and EMA facilitate generic approvals based on bioequivalence, supporting market proliferation.
• Price pressures from health insurers, government payers, and price control policies in emerging markets modulate revenue streams.

4. Emerging Market Expansion

• Growing healthcare infrastructure in Asia-Pacific, Latin America, and Africa enlarges the LASIX consumer base.
• Increasing awareness and diagnosis of conditions requiring diuretics promote further demand.

---

How Are Revenue Streams and Market Shares Distributed?

Parameter	Details
Global Market Size (2022)	Estimated at $600 million USD, predominantly from generic sales (Ref: GlobalData).
United States Market Share	Approx. 50-55% of revenue; driven mainly by generic competition.
Key Players	Major manufacturers include Teva Pharmaceuticals, Sandoz, Mylan, and local generics producers globally.
Pricing Trends	US average wholesale price (AWP): approximately $0.02 per tablet; in emerging markets, prices are substantially lower (~$0.005/tablet).

Revenue Projections (2023–2030)

Year	Projected Market Size (USD billion)	Growth Rate	Comments
2023	$0.60	—	Baseline
2025	$0.65	3.0%	Steady demand, stable pricing
2030	$0.75	4.0% annually	Growing demand in emerging markets, slight price recovery possible

Note: The compound annual growth rate (CAGR) for LASIX is modest, around 2-4%, primarily due to market saturation in mature economies and increased competition.

---

What Are the Regulatory and Manufacturing Challenges?

Regulatory Landscape

• Generic Approval Protocols: Strict bioequivalence requirements remain a barrier for some emerging market manufacturers.
• Quality Standards: Ensuring high-quality manufacturing amid cost pressures is vital to maintaining market share.

Manufacturing Considerations

• Supply Chain Stability: Raw material sourcing (e.g., active pharmaceutical ingredients, APIs) faces disruptions; notably, recent shortages of certain diuretics have influenced supply.
• Cost of Production: Continued efforts to optimize manufacturing processes (e.g., continuous manufacturing) aim to lower costs and boost margins.

---

How Is Competitive Pressures Shaping the Market?

Factor	Impact
Price Competition	Intense; prices have declined by up to 70% since patent expiry (Ref: FDA Drug Pricing Data).
Alternative Diuretics	Development of novel agents (e.g., torsemide) offers competition but currently accounts for a small niche due to LASIX’s established position.
Combination Therapies	Limited; LASIX is not often combined with other drugs, maintaining focus on monotherapy volume.

Future Competitive Strategies

• Manufacturers may explore biosimilar development or combination formulations to regain pricing power.
• Digital health integration to optimize therapy adherence and outcomes.

---

What Are the Future Market Opportunities and Risks?

Opportunities

• Expansion in Developing Countries: Population growth and rising disease burden continue to provide growth avenues.
• Product Line Extensions: Formulations such as extended-release tablets or injectable forms can fulfill specific clinical needs.
• Policy Support: Governments’ focus on essential medicines can favor stable demand.

Risks

• Regulatory Stringency: New bioequivalence standards or Quality by Design (QbD) policies could delay approvals.
• Market Saturation: Mature markets may see plateauing revenues; reliance on volume scaling.
• Alternatives and Innovations: Emergence of new diuretics or therapies explaining the same indication could reduce LASIX’s relevance.

---

How Do Regulatory Policies Influence the Future?

Region	Policy Impact	Key Regulations	Implications
US	Price Control & Generics	Medicaid Drug Rebate Program, Competitive Generic Exclusivity	Drives prices down, enhances volume but limits margins.
EU	NHS policies & tendering	EMA bioequivalence approvals	Focus on cost efficiency drives generic utilization.
Emerging Markets	Variable regulation	Policy reforms aim for increased access	Larger markets but variable quality standards.

How Does Competitive Pricing Impact LASIX Revenue?

Price Scenario	Volume Assumption	Revenue Impact	Notes
Stable Price	10 billion tablets/year	~$200 million/year	Consistent in mature markets
Price Decline 20%	Same volume	~$160 million/year	Increased competition pressures
Price Drop 50%	Same volume	~$100 million/year	Possible in certain jurisdictions due to aggressive generics

---

Key Industry Trends and Their Financial Implications

Trend	Impact	Strategic Response
Growing penetration in unserved markets	Revenue growth potential	Market development programs, local manufacturing
Cost pressures	Margins compression	Process optimization, supply chain innovation
Digital health integration	Improved adherence, volume stability	Digital therapeutic monitoring

---

Key Takeaways

• LASIX remains a foundational diuretic with a stable global demand driven by aging populations and the high prevalence of cardiovascular and renal diseases.
• The market faces continuous price erosion owing to generics, with projected modest growth driven primarily by emerging markets.
• Regulatory environments favor rapid generic approval, but quality enforcement ensures market stability.
• Market expansion opportunities exist in developing countries, but competition from alternative agents and new therapies pose threats.
• Efficient manufacturing, strategic regional expansion, and product innovation are essential to sustain profitability.
• The overall financial trajectory indicates slow but steady growth, with revenues likely stabilizing in mature markets and expanding in underserved regions.

---

FAQs

1. How does patent expiration affect LASIX pricing and revenues?
Patent expiration in the mid-1980s led to a flood of generic versions, drastically lowering prices and revenues. While revenues from branded LASIX declined, generic competition allowed volume-driven growth, stabilizing overall market size.

2. Are there any new formulations or delivery methods for LASIX?
Currently, LASIX is primarily available as tablets; however, research into extended-release formulations and injectables exists but is not widely commercialized. Such innovations could improve patient adherence and clinical outcomes.

3. What are the primary markets influencing LASIX sales?
The United States remains the dominant market (~50-55%), followed by Europe, Asia-Pacific, and emerging regions in Latin America, Africa, and the Middle East.

4. How do regulatory policies across regions impact LASIX’s market trajectory?
Strict bioequivalence standards facilitate rapid approval of generics in developed markets, maintaining supply but exerting price pressure. Developing regions may face regulatory hurdles, impacting market entry strategies.

5. What is the outlook for LASIX in the context of modern cardiovascular therapies?
While newer agents with specific mechanisms of action are emerging, LASIX’s cost-effectiveness and extensive clinical history sustain its relevance, especially in resource-limited settings. However, evolving treatment paradigms could influence future utilization rates.

---

References

[1] World Health Organization (WHO). "Cardiovascular Diseases (CVD)." 2021.
[2] GlobalData. "Diuretic Market Analysis," 2022.
[3] FDA Drug Pricing Data. "Generic Drug Price Trends," 2021.
[4] European Medicines Agency (EMA). "Bioequivalence Guidelines," 2020.
[5] Industry Reports. "Global Diuretics Market Forecast," 2022.